tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SRPT Stock Latest News

Sarepta receives approval to start SRP-1005 trial in New Zealand
The FlySarepta receives approval to start SRP-1005 trial in New Zealand
10d ago
SRPT
Sarepta assumed with an Equal Weight at Barclays
PremiumThe Fly
Sarepta assumed with an Equal Weight at Barclays
17d ago
SRPT
Sarepta price target raised to $22 from $15 at Baird
PremiumThe Fly
Sarepta price target raised to $22 from $15 at Baird
18d ago
SRPT
Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data, Supporting Sell/High Risk Rating
PremiumRatings
Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data, Supporting Sell/High Risk Rating
18d ago
SRPT
H.C. Wainwright reiterates Sell on Sarepta after 3-year data
PremiumThe Fly
H.C. Wainwright reiterates Sell on Sarepta after 3-year data
18d ago
SRPT
Midday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave
PremiumThe FlyMidday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave
19d ago
LE
AMP
Sarepta rises 14.1%
Premium
The Fly
Sarepta rises 14.1%
19d ago
SRPT
Morning Movers: USA Rare Earth surges after government funding pact
Premium
The Fly
Morning Movers: USA Rare Earth surges after government funding pact
19d ago
AAUC
CRWV
Sarepta reports ‘positive’ topline three-year EMBARK results for Elevidys
PremiumThe Fly
Sarepta reports ‘positive’ topline three-year EMBARK results for Elevidys
19d ago
SRPT
Sarepta to report 3-year topline data from Embark Part 1 study
PremiumThe Fly
Sarepta to report 3-year topline data from Embark Part 1 study
19d ago
SRPT
Sarepta sales of Elevidys ‘cratering fast,’ says H.C. Wainwright
PremiumThe Fly
Sarepta sales of Elevidys ‘cratering fast,’ says H.C. Wainwright
1M ago
SRPT
Tempered Growth Outlook and Heightened Regulatory Risk Drive Sell Rating on Sarepta Therapeutics
PremiumRatings
Tempered Growth Outlook and Heightened Regulatory Risk Drive Sell Rating on Sarepta Therapeutics
1M ago
SRPT
Sarepta price target raised to $19 from $18 at BofA
PremiumThe FlySarepta price target raised to $19 from $18 at BofA
1M ago
SRPT
Balanced Risk Profile Amid Elevidys Uncertainty and PMO Regulatory Headwinds Supports Hold on Sarepta
Premium
Ratings
Balanced Risk Profile Amid Elevidys Uncertainty and PMO Regulatory Headwinds Supports Hold on Sarepta
1M ago
SRPT
Sarepta Therapeutics: Resilient Fundamentals, Elevidys Recovery, and Pipeline Catalysts Underscore Attractive Buy‑Rated Upside
Premium
Ratings
Sarepta Therapeutics: Resilient Fundamentals, Elevidys Recovery, and Pipeline Catalysts Underscore Attractive Buy‑Rated Upside
1M ago
SRPT
Sarepta price action likely driven by softer Elevidys Q4 sales, says Jefferies
PremiumThe Fly
Sarepta price action likely driven by softer Elevidys Q4 sales, says Jefferies
1M ago
SRPT
Sarepta falls 10% to $21.37 after reporting preliminary Q4 revenue
PremiumThe Fly
Sarepta falls 10% to $21.37 after reporting preliminary Q4 revenue
1M ago
SRPT
Sarepta reports preliminary Q4 net product revenue $369.9M
PremiumThe Fly
Sarepta reports preliminary Q4 net product revenue $369.9M
1M ago
SRPT
Sarepta submits clinical trial application for study SRP-1005-101 to Medsafe
PremiumThe Fly
Sarepta submits clinical trial application for study SRP-1005-101 to Medsafe
1M ago
SRPT
Sarepta Therapeutics Extends Debt Maturities with New Notes
PremiumCompany AnnouncementsSarepta Therapeutics Extends Debt Maturities with New Notes
2M ago
8K
SRPT
HHS adds Duchenne muscular dystrophy to recommended screening panel
Premium
The Fly
HHS adds Duchenne muscular dystrophy to recommended screening panel
2M ago
SLDB
SRPT
Vertiv, Affirm, Sarepta, Micron, PepsiCo: Trending by Analysts
Premium
Weekend Updates
Vertiv, Affirm, Sarepta, Micron, PepsiCo: Trending by Analysts
2M ago
MU
PEP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >